Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

generic

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

Novartis building

Novartis will file heart failure drug before year-end

New data reinforces view that LCZ696 can reduce cardiovascular deaths

Novartis building

Novartis: novel antimalarial is ‘game-changing’

Says cipargamin could be first new class of malaria drugs in 20 years

Novartis building

Novartis’ glaucoma combo cleared in Europe

Simbrinza approved to treat eye condition

- PMLiVE

Neupogen will be first biologic on FDA biosimilars pathway

US regulator will review Novartis’  version of Amgen's Neupogen (filgrastim) over the coming months

Novartis building

Novartis’ vaccine sales decline ahead of GSK transfer

Only business not to show growth during second quarter of 2014

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Novartis buys rights to Google’s ‘smart lens’ technology

Pharma company's eye unit Alcon will focus on uses in diabetes and presbyopia

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis

Data reinforces secukinumab's position among new generation of biologic

France flag

Pharma criticises France’s backing for off-label Avastin use

EFPIA weighs in on proposal to move wet AMD patients to the drug as a cheaper alternative

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links